Cogent Biosciences Q3 net loss widens to $111.4 million on launch preparation costs
Cogent Biosciences reported third quarter 2026 results, with a net loss of $111.4 million compared with $80.9 million a year earlier. Higher general and administrative spending tied to commercial readiness for bezuclastinib drove most of the increase, and the filing reports no revenue line. The company said its $791.1 million cash balance is expected to fund operations into late 2028.
Key points
- Net loss was $111.4 million for the quarter ended September 30, 2026, versus $80.9 million for the same period of 2025.
- General and administrative expenses rose to $42.1 million from $14.4 million, mainly for commercial readiness ahead of a potential bezuclastinib launch.
- Research and development expenses were $75.1 million, up from $69.0 million.
- Cash, cash equivalents and marketable securities were $791.1 million as of September 30, 2026, versus $900.8 million at December 31, 2025 and $792.3 million at June 30, 2026.
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.